[HTML][HTML] Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits

N Govsyeyev, M Nehler, MS Conte, S Debus… - Journal of Vascular …, 2023 - Elsevier
Background Patients with peripheral artery disease (PAD) requiring lower extremity
revascularization (LER) have a high risk of adverse limb and cardiovascular events. The …

Effect of rivaroxaban and aspirin in patients with peripheral artery disease undergoing surgical revascularization: insights from the VOYAGER PAD trial

ES Debus, MR Nehler, N Govsyeyev, RM Bauersachs… - Circulation, 2021 - Am Heart Assoc
Background: Patients with peripheral artery disease requiring lower extremity
revascularization (LER) are at high risk of adverse limb and cardiovascular events. The …

Total ischemic event reduction with rivaroxaban after peripheral arterial revascularization in the VOYAGER PAD trial

RM Bauersachs, M Szarek, M Brodmann, I Gudz… - Journal of the American …, 2021 - jacc.org
Background Patients with peripheral artery disease (PAD) undergoing lower extremity
revascularization (LER) are at high risk of major adverse limb and cardiovascular events …

Rivaroxaban and risk of venous thromboembolism in patients with symptomatic peripheral artery disease after lower extremity revascularization

CN Hess, M Szarek, SS Anand… - JAMA Network …, 2022 - jamanetwork.com
Importance Prior studies have observed an association between the burden of
atherosclerotic vascular disease and the risk of venous thromboembolism (VTE). The …

Rivaroxaban in peripheral artery disease after revascularization

MP Bonaca, RM Bauersachs, SS Anand… - … England Journal of …, 2020 - Mass Medical Soc
Background Patients with peripheral artery disease who have undergone lower-extremity
revascularization are at high risk for major adverse limb and cardiovascular events. The …

Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease …

WH Capell, MP Bonaca, MR Nehler, E Chen… - American heart …, 2018 - Elsevier
Background Patients with peripheral artery disease (PAD) undergoing a lower-extremity
revascularization are at heightened risk for ischemic cardiac and limb events. Although …

Efficacy and safety of rivaroxaban therapy for patients with peripheral artery disease: a systematic review and meta-analysis

Y Hao, W Han, D Mou, J Wang - Vascular and Endovascular …, 2021 - journals.sagepub.com
Objective: We performed a systematic review and meta-analysis to evaluate the efficacy and
safety of rivaroxaban in patients with PAD for the first time. Methods: We searched …

Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a “CASPAR like” outcome from VOYAGER PAD

MP Bonaca, M Szarek, ES Debus, MR Nehler… - Clinical …, 2022 - Wiley Online Library
Abstract Background The Clopidogrel and Acetylsalicylic Acid in Bypass Surgery for
Peripheral Arterial Disease (CASPAR) trial is the only large, double‐blind, placebo …

Rivaroxaban plus aspirin versus aspirin alone after endovascular revascularization for symptomatic PAD: insights from VOYAGER PAD

J Rymer, SS Anand, E Sebastian Debus, LP Haskell… - Circulation, 2023 - Am Heart Assoc
BACKGROUND: Rivaroxaban plus aspirin compared with aspirin alone reduced major
cardiac and ischemic limb events after lower extremity revascularization (LER) in the …

Rivaroxaban and aspirin in peripheral artery disease lower extremity revascularization: impact of concomitant clopidogrel on efficacy and safety

WR Hiatt, MP Bonaca, MR Patel, MR Nehler… - Circulation, 2020 - Am Heart Assoc
Background: The VOYAGER PAD trial (Vascular Outcomes Study of ASA Along With
Rivaroxaban in Endovascular or Surgical Limb Revascularization for Peripheral Artery …